Literature DB >> 15996412

Microvascular embolization following polidocanol microfoam sclerosant administration.

David M Eckmann1, Shunji Kobayashi, Min Li.   

Abstract

BACKGROUND: Intravenous microfoam sclerotherapy solutions can potentially cause cerebrovascular arterial embolization.
OBJECTIVE: To determine the relationship between polidocanol microfoam formulation and arteriolar embolization bubble lodging and clearance in vivo.
METHODS: Three polidocanol microfoams (one made by the double-syringe method using air and two Varisolve (Provensis, Inc., West Conshohocken, PA, USA) formulations using different physiologic gas mixtures composed primarily of oxygen and carbon dioxide and dispensed from a proprietary canister mechanism) were mixed with venous blood and injected into the rat cremaster arterial microcirculation. Bubble dimensions and dynamics were recorded using intravital microscopy.
RESULTS: Bubble entry frequency, size, and dynamics depended on microfoam formulation. Air-based bubbles (2.72 1.38 nL; n = 21) lodged, obliterating blood flow. Varisolve bubbles (0.20 0.02 nL; n = 2 and 0.53 0.27 nL; n = 27 for the two gas compositions) entered but either did not lodge or cleared within seconds. Bubble size and number were different among these microfoams.
CONCLUSIONS: Both Varisolve formulations produced smaller embolism bubbles than occurred with air-based microfoam. Rapid clearance of Varisolve bubbles suggests that they are so small that they do not have adequate surface area available for significant binding interactions with arteriolar endothelium. Larger air-based bubbles obstruct arteriolar vessels and block blood flow.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15996412     DOI: 10.1111/j.1524-4725.2005.31605

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  8 in total

1.  Compression sclerotherapy for primary valvular insufficiency -from liquid to foam-.

Authors:  Takashi Yamaki
Journal:  Ann Vasc Dis       Date:  2010-07-21

2.  In vitro surfactant mitigation of gas bubble contact-induced endothelial cell death.

Authors:  Shunji Kobayashi; Steven D Crooks; David M Eckmann
Journal:  Undersea Hyperb Med       Date:  2011 Jan-Feb       Impact factor: 0.698

3.  Effect of a soluble surfactant on a finite sized bubble motion in a blood vessel.

Authors:  T N Swaminathan; K Mukundakrishnan; P S Ayyaswamy; D M Eckmann
Journal:  J Fluid Mech       Date:  2010-01-01       Impact factor: 3.627

Review 4.  Polidocanol for endovenous microfoam sclerosant therapy.

Authors:  David M Eckmann
Journal:  Expert Opin Investig Drugs       Date:  2009-12       Impact factor: 6.206

5.  Benefits of polidocanol endovenous microfoam (Varithena®) compared with physician-compounded foams.

Authors:  Dario Carugo; Dyan N Ankrett; Xuefeng Zhao; Xunli Zhang; Martyn Hill; Vincent O'Byrne; James Hoad; Mehreen Arif; David D I Wright; Andrew L Lewis
Journal:  Phlebology       Date:  2015-06-01       Impact factor: 1.740

6.  The Efficacy and Health Economics of Different Treatments for Type 1 Cesarean Scar Pregnancy.

Authors:  Tingting Hong; Zeying Chai; Manman Liu; Lingzhi Zheng; Feng Qi
Journal:  Front Pharmacol       Date:  2022-01-28       Impact factor: 5.810

7.  Surfactant reduction of cerebral infarct size and behavioral deficit in a rat model of cerebrovascular arterial gas embolism.

Authors:  David M Eckmann; Stephen C Armstead
Journal:  J Appl Physiol (1985)       Date:  2013-07-11

8.  The role of clinically-relevant parameters on the cohesiveness of sclerosing foams in a biomimetic vein model.

Authors:  Dario Carugo; Dyan N Ankrett; Vincent O'Byrne; David D I Wright; Andrew L Lewis; Martyn Hill; Xunli Zhang
Journal:  J Mater Sci Mater Med       Date:  2015-10-08       Impact factor: 3.896

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.